As well as being a contract research organization, Cyprotex spend considerable resource performing research into the development and testing of in vitro and in silico methods as alternatives to animal testing. In September, our scientists have been busy presenting this research. At Eurotox, Cyprotex presented three posters - two on 3D cell-based models and one on validation of an ocular model as part of the CON4EI (part of CEFIC) project. At the DMG meeting in London, we presented our research on skin metabolism. Our webinar on genotoxicity testing strategies also attracted a large audience. All of these resources are available to you below.
Other important announcements in September have included introduction of an additional 8 transporter assays, and expansion of our metabolite identification service for the analysis of human clinical samples. We are also delighted to welcome our new Director of US Operations, Dr Monica Metea, who joined the company on 26th September. The role will provide operational and scientific leadership to our Watertown, MA and Kalamazoo, MI facilities.